Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Methyclothiazide (Aquatensen) 是一种具有口服活性的利尿剂,也是一种降压剂。它能够拮抗体外的电压依赖性钙通道的 (VDCC) 活性,也可以抑制内源性血管收缩刺激导致的血管反应。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 278 | 现货 | ||
25 mg | 待询 | 现货 | ||
50 mg | 待询 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 242 | 现货 |
产品描述 | Methyclothiazide (Aquatensen) is a substituted benzothiadiazide, used to treat high blood pressure and fluid retention caused by various conditions including heart disease. |
体外活性 | Methyclothiazide (0.1 mM) reduces Ca2+ contractures with maximal inhibition of 90.4% in SHR aortic rings with endothelium. The inhibitory effect of Methyclothiazide (0.1 mM) on Ca2+ contracture is significantly but not totally abolished by the NO synthase inhibitor in SHR aortic rings with functional endothelium. [1] Methyclothiazide (0.1 mM) induces endothelium-dependent inhibition of the vasoconstrictor responses to NE and AVP only in aortas from spontaneously hypertensive rats (SHR) rather than normotensive Wistar Kyoto rats (WKY), and the maximal vasoconstrictive effect of NE and AVP is decreased by 59% and 32.3%, respectively. [2] Methyclothiazide (3.5 mM) inhibits renin release in rat kidney slices. [3] |
体内活性 | Methyclothiazide (0.1 g/L for the first 5 weeks and 0.2 g/L for the second 2 weeks, drinking water) attenuates development of hypertension in salt-sensitive (DS) rats, but does not affect blood pressure in salt-resistant (DR) ones. [4] The methyclothiazide-treated DOCA-salt rats weigh less than controls or the nonsupplemented DOCA-salt rats at weeks 3 and 4. Methyclothiazide added to the drinking water of DOCA-salt rats attenuates the elevation of blood pressure. [5] |
别名 | Duretic, Enduron, 甲氯噻嗪, Aquatensen |
分子量 | 360.24 |
分子式 | C9H11Cl2N3O4S2 |
CAS No. | 135-07-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 72 mg/mL (199.86 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 4 mg/mL (11.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.7759 mL | 13.8796 mL | 27.7593 mL | 69.3982 mL |
5 mM | 0.5552 mL | 2.7759 mL | 5.5519 mL | 13.8796 mL | |
10 mM | 0.2776 mL | 1.388 mL | 2.7759 mL | 6.9398 mL | |
DMSO | 20 mM | 0.1388 mL | 0.694 mL | 1.388 mL | 3.4699 mL |
50 mM | 0.0555 mL | 0.2776 mL | 0.5552 mL | 1.388 mL | |
100 mM | 0.0278 mL | 0.1388 mL | 0.2776 mL | 0.694 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Methyclothiazide 135-07-9 Metabolism Others Carbonic Anhydrase Duretic Enduron ?stroke,?heart attack,thiazide diuretics Inhibitor inhibit edema blood 甲氯噻嗪 high pressure Carbonate dehydratase Aquatensen inhibitor